Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma - Summary - MDSpire

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma

  • By

  • Tim Schlierkamp-Voosen

  • Markus Barden

  • Helena Janning

  • Marcell Kaljanac

  • Dennis Christoph Harrer

  • Celine Dreger

  • Kathrin Hammon

  • Moritz Ertelt

  • Clara T. Schoeder

  • Hólmfridur Rósa Halldórsdóttir

  • Carlos Rodriguez-Pardo

  • Sine Reker Hadrup

  • Simone Thomas

  • Hinrich Abken

  • April 30, 2026

  • 0 min

Share

Objective:

To enhance the efficacy of CD19 CAR T cells against B-cell malignancies by blocking the CD30–CD30L interaction.

Key Findings:
  • CD30/CD19 CAR T cells were more effective in eliminating CD19+ leukemia cells than canonical CD19 CAR T cells.
  • Blocking CD30–CD30L interaction resulted in enhanced T-cell functionality and reduced Th2 polarization.
  • The order of scFv in the bispecific CAR (CD30/CD19) was superior for optimal synaptic gap formation.
Interpretation:

The study demonstrates that inhibiting the CD30–CD30L interaction can significantly improve the antitumor efficacy of CAR T cells against B-cell malignancies by enhancing their activation and cytotoxic potential.

Limitations:
  • The study primarily focuses on in vitro results; in vivo efficacy and safety need further investigation.
  • Potential long-term effects of CD30 blockade on T-cell memory and functionality remain unclear.
Conclusion:

This research provides a promising strategy to enhance the effectiveness of CD19 CAR T-cell therapy by targeting the CD30 pathway, potentially reducing early relapse rates in B-cell malignancies.

Original Source(s)

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma

  • by Tim Schlierkamp-Voosen, Markus Barden, Helena Janning, Marcell Kaljanac, Dennis Christoph Harrer, Celine Dreger, Kathrin Hammon, Moritz Ertelt, Clara T. Schoeder, Hólmfridur Rósa Halldórsdóttir, Carlos Rodriguez-Pardo, Sine Reker Hadrup, Simone Thomas, Hinrich Abken

  • April 30, 2026

Related Content

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min
Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

Roswell Park’s Stem Cell Transplant Program Recognized by Optum as Center of Excellence

Health services leader Optum has recognized Roswell Park Comprehensive Cancer Center as a Center of Excellence (COE) for the stem cell transplant program provided through its Transplant & Cellular Therapy Center.

  • by

  • August 7, 2025

  • 3 min